{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 11 of 61', 'Medtronic', '3. Symptomatic urinary tract infection (UTI)', '4.', 'Have primary stress incontinence or mixed incontinence', 'where the stress component overrides the urge component', '5. Treatment of urinary symptoms with botulinum toxin in the', 'past 9 months or any plan to have botulinum toxin treatment', 'during the study', '6.', 'Implanted with a neurostimulator, pacemaker, or defibrillator', '7. Have knowledge of planned MRIs, diathermy, microwave', 'exposure, high output ultrasonic exposure, or RF energy', 'exposure not included within the scanning conditions', 'provided with the MRI Guidelines for InterStim Therapy', '8.', 'Women who are pregnant or planning to become pregnant', '9.', 'Characteristics indicating a poor understanding of the study', 'or characteristics that indicate the subject may have poor', 'compliance with the study protocol requirements', '10. Currently enrolled or planning to enroll in a potentially', 'confounding clinical study during the course of the study (co-', 'enrollment in concurrent studies is only allowed when', 'documented pre-approval is obtained from the Medtronic', 'study manager (or designee)', 'Study Procedures and', 'Study Visits:', 'Assessments', '1. Enrollment/ Baseline', '2. Tined Lead or temporary Test Stimulation Lead Implant', '3. Therapy Evaluation', '4. Tined Lead (if applicable) / Neurostimulator Device Implant', '(randomization procedures)', '5. One Week Follow-up Visit', '6. Six Week Follow-up Visit', '7. Twelve Week Follow-up Visit', 'Enrollment/Baseline', 'Subjects are considered enrolled at the time the study-specific', 'informed consent is signed. Each subject must meet all the inclusion', 'and no exclusion criteria to be eligible to participate in the study. At', 'the enrollment/baseline visit, data will be gathered from subjects', 'including relevant medical history and concomitant OAB medication.', 'Subjects will complete the following questionnaire:', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 12 of 61', 'Medtronic', 'Overactive Bladder Symptoms Quality of Life', 'Questionnaire (ICIQ-OABqol)', 'The voiding diary will be explained and given to the subject to be', 'completed for 3 consecutive days. The 3-day voiding diary must be', 'completed along with confirmation that the subject is not pregnant or', 'planning to become pregnant during participation in the trial, as part', 'of the assessment for study eligibility.', 'Tined Lead or temporary Test Stimulation Lead Implant', 'If using basic evaluation, the temporary Test Stimulation Lead should', 'be placed in accordance with the InterStim system Test Stimulation', 'Lead Kit and Test Stimulation Lead Technical Manual.', 'If using advanced evaluation, the InterStim tined lead should be', 'placed in accordance with the InterStim Therapy Model 3889 Lead', 'Implant Manual.', 'For both advanced and basic evaluation, throughout the study,', 'unilateral stimulation is required.', 'Settings may be set per Investigator discretion during the therapy', 'evaluation period. Any', 'reportable', 'adverse events/device deficiencies will be documented and reported.', 'Therapy Evaluation', 'The therapy evaluation period should be conducted in accordance', 'with the InterStim II System Labeling using the Verify External', 'Neurostimulator. The therapy evaluation period must not exceed', 'either 14 days if using InterStim tined lead, or 7 days if using the', 'temporary Test Stimulation Lead or the approved duration in the', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 13 of 61', 'Medtronic', 'commercially available labeling in the respective country. A 3-day', 'voiding diary will be completed towards the end of the therapy', 'evaluation period. A minimum of a 50% improvement in voiding', 'symptoms (either UUI or UF), or return to normal voiding of < 8 voids', 'per day for UF subjects, is required in order to qualify for a', 'neurostimulator implant in the study. Any', 'reportable adverse events/device deficiencies will be', 'documented and reported.', 'Tined Lead (if applicable) / Neurostimulator Device Implant', '(randomization procedures)', 'Once the subject qualifies for the neurostimulator device implant, site', 'personnel may proceed with the Neurostimulator Device Implant Visit', 'and randomization procedures. If a subject does not qualify for the', 'neurostimulator device implant, they will be exited from the study.', 'For subjects who qualify for device implant following a successful', 'basic evaluation, the InterStim tined lead should be placed in', 'accordance with the InterStim Therapy Model 3889 Lead Implant', 'Manual.', 'At the time of the neurostimulator device implant, site personnel will', 'obtain a randomization assignment to randomize each subject to one', 'of the following therapy amplitudes: sensory threshold, 50% of', 'sensory threshold or 80% of sensory threshold. Subjects are blinded', 'to their randomized setting. All measures should be taken to ensure', 'that the subject does not become unblinded to their randomization', 'throughout the study.', 'Subjects will be implanted with the Neurostimulator in accordance', 'with the InterStim Therapy InterStim II Model 3058 Neurostimulator', 'Implant Manual.', 'After the device implant is complete, it is required that subjects be', 'programmed to 14 hertz (Hz), 210 s pulse width (pw) and continuous', 'stimulation for the duration of the study. During programming', \"throughout the study, the subject's sensory threshold amplitude will\", 'be determined by following this protocol: start at 0.05 volts (V) and', 'increase voltage in 0.05 V increments until the subject reports', 'sensation. Prior to discharge, the amplitude at each electrode', 'configuration that elicits a sensory response must be determined in', 'seated', 'positions. As part of the programming,', 'impedance checks should be completed during each study visit.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}